Tufts University School of Medicine researchers identify a key testing area that could help clinicians diagnose the disease sooner and determine efficacy of treatments
The ongoing antidepressant and anti-anxiety benefits of brexanolone, a drug approved for the treatment of postpartum depression, for weeks after treatment may lie in how it alters oscillations in regions of the brain associated with mood